Brief: Agenus and Zydus Lifesciences Enter $141 Mln Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
03/06/2025 12:03
June 3 (Reuters) - Agenus Inc AGEN.O: AGENUS AND ZYDUS LIFESCIENCES ENTER $141M STRATEGIC COLLABORATION TO ADVANCE BOT/BAL, EXPAND ZYDUS’ BIOLOGICS MANUFACTURING IN THE US AGENUS INC: $75M UPFRONT PAYMENT TO AGENUS FOR TRANSFER OF MANUFACTURING ASSETS AGENUS: ZYDUS TO MAKE A STRATEGIC EQUITY INVESTMENT IN AGENUS BY PURCHASING ABOUT 2.1 MILLION SHARES OF COMMON STOCK AT $7.50 PER SHARE Source text: ID:nBw8lBB9Sa Further company coverage: AGEN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income